All News

Creating meaningful content on social media can be broken down into 3 steps: planning, creating, and refining.

The increasing prices of the drugs used to treat hookworm, roundworm (ascariasis), and whipworm (trichuriasis) is driving increased costs for patients with Medicaid or private insurance, as well as a potential decrease in the quality of care those patients receive.

This week on Pharmacy Times, there are a number of important topics that will be covered and posted throughout the week.

Findings show that an inflamed environment allows clostridioides difficile to thrive in an environment that is inhospitable to competing bacteria.

Experts in the management of VTE discuss the deterrents among providers, patients, and pharmacists, specifically looking at the various dosage forms of treatment.

The FDA announced that it will hold a public meeting of the Oncologic Drugs Advisory Committee from April 27 to 29 to address the indications granted accelerated approval for 6 therapies.

Bristol Myers Squibb and bluebird bio are seeking FDA approval for ide-cel as a standard therapy for relapsed myeloma, with a decision expected by the end of March.

A panel of experts discuss the risks vs benefits of prophylactic care for patients to prevent VTE.

The investigators observed a near normal age distribution among patients with long-term COVID-19 symptoms, including children.

The pharmaceutical supply chain, while always central to health care, will play an even more crucial role as the pandemic continues to threaten the financial viability of hospitals and health systems, large and small.

The sNDA seeks to expand the label of cabotegravir and rilipivirine to include dosing of every 2 months for the treatment of HIV-1 infection in virologically suppressed adults (HIV-1 RNA less than 50 copies per milliliter) on a stable regimen.

The critical component is omega-3 fatty acids, which was associated with a lower risk of major CVD events, such as heart attacks and strokes, by about one-sixth in high-risk people who ate 2 servings of fish rich in omega-3 each week.

Cognitive fatigue, which is defined as a troublesome symptom among healthy and clinical populations, is a major research focus at Kessler Foundation.

Fecal microbiota transplants (FMT) are highly successful in treating patients with Clostridioides difficile (C diff) infections, according to a study by the University of Birmingham.

For millennia, humans have linked feces and disease, making the connection that since it’s gross, it’s probably also harmful.

Best practices for prescribing an immunomodulatory-based therapy or a proteasome inhibitor as treatment for relapsed/refractory multiple myeloma.

Considerations for treating patients with relapsed/refractory multiple myeloma with elotuzumab, daratumumab, or isatuximab based on more recent clinical trial data and differences between each treatment option.

Variables considered by healthcare professionals when selecting an appropriate backbone regimen to manage a patient with relapsed or refractory multiple myeloma.

Healthcare stakeholders comment on current practices managing patients with relapsed/refractory multiple myeloma during the COVID pandemic and discuss their comfort switching patients over from intravenous daratumumab to subcutaneous daratumumab.

Factors that influence treatment selection for relapsed or refractory multiple myeloma, and suggestions to help streamline decision making and address limitations associated with current treatment pathways.

A historical review of treatment advances in relapsed/refractory multiple myeloma and criteria used to define relapsed or refractory disease.

The FDA has granted a fast track designation to poziotinib for use in previously treated non-small cell lung cancer patients with HER2 exon 20 mutations.

With schools around the nation reopening, it is time to think about managing diabetes in the classroom.

Danielle DiBari, the chief pharmacy officer and senior vice president of business operations for NYC Health + Hospitals, discusses some of the challenges involved in coordinating vaccine distribution across New York’s public health system.

The receipt of preventive care for youth enrolled in Medicaid managed care fell significantly short of the annual goal set by the Centers for Medicare and Medicaid Services (CMS).

The oral, next-generation vascular endothelial growth factor tyrosine kinase inhibitor is the first therapy approved for this patient population following 2 or more prior systemic therapies.

An ongoing phase 2 clinical study has begun to vaccinate patients with a modified version of Moderna’s COVID-19 vaccine.

A recent research review found that a large proportion of COVID-19 survivors will be affected by neuropsychiatric and cognitive complications.